The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).
GB News on MSN13h
New jab offered to millions of pensioners and pregnant women 'could cause neurological illness' as health chiefs issue vaccine safety alertUS health officials have issued a warning linking RSV vaccines to an increased risk of a serious neurological condition. The ...
A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...
US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is ...
Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...
The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback